{"analyses":[{"ciLowerLimit":"0.54","ciNumSides":"TWO_SIDED","ciPctValue":"80","ciUpperLimit":"0.95","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.06","pValueComment":"1-sided p-value","paramType":"Hazard Ratio (HR)","paramValue":"0.71","statisticalComment":"Stratified log rank test by performance status and histology type.","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.5","upperLimit":"8.5","value":"7.2"},{"groupId":"OG001","lowerLimit":"4.6","upperLimit":"6.2","value":"5.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"47"}],"units":"Participants"}],"description":"From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause. Patients last known to be alive and progression free are censored at date of last contact. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v 1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesions, or the appearance of new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 2 hours on day 1 and cediranib maleate PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive cediranib maleate alone PO QD in the absence of disease progression or unacceptable toxicity.\n\nCediranib Maleate: Given orally\n\nCisplatin: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPemetrexed Disodium: Given IV","id":"OG000","title":"Phase II Cisplatin-pemetrexed Cediranib 20mg"},{"description":"Patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 2 hours on day 1 and placebo PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive placebo alone PO QD in the absence of disease progression or unacceptable toxicity.\n\nPlacebo: Given orally\n\nCisplatin: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPemetrexed Disodium: Given IV","id":"OG001","title":"Phase II Cisplatin-pemetrexed Placebo"}],"paramType":"MEDIAN","populationDescription":"Only eligible and analyzable patients were included.","reportingStatus":"POSTED","timeFrame":"From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, whichever came first, assessed up to 5 years.Disease assessment will be repeated every 6 weeks until disease progression.","title":"Progression-free Survival (Phase II)","type":"PRIMARY","unitOfMeasure":"month"}